

National Pharmaceutical Pricing Authority

Subject: Minutes of the 46th meeting of the Multidisciplinary Committee of Experts held on 19.10.2022 at 11:30 AM.

46th meeting of the "Multidisciplinary Committee of Experts" was held on 19.10.2022 at 11:30 AM under the convenorship of Shri Manmohan Sachdeva, Advisor (Cost), through video-conferencing. The following members attended the meeting: -

1. Shri A.K. Pradhan, Jt. Drugs Controller, CDSCO through video conferencing
2. Dr. J. J. Cherian, Scientist-D, ICMR through video conferencing
3. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli through video conferencing
4. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoea Commission – Co-opted member through video conferencing
5. Prof. Y. K. Gupta, Principal Scientific Advisor (projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member through video conferencing
6. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS- New Delhi through video conferencing

The following officers of NPPA attended and presented the cases before the Committee

1. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA

1. Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013 – Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablet.

1.1 The Committee noted that seven applications have been received for retail price fixation of four Fixed Dose Combinations (FDCs) of Sitagliptin and Metformin tablets i.e. (i) Sitagliptin 50 mg + Metformin 500 mg tablet, (ii) Sitagliptin 50 mg + Metformin 1000 mg tablet, (iii) Sitagliptin 100 mg + Metformin 1000 mg (extended release) tablet, (iv) Sitagliptin 50 mg + Metformin 500 mg (extended release) tablet, (v) Sitagliptin 50 mg + Metformin 1000 mg (extended release) tablet, and (vi) Sitagliptin 100 mg + Metformin 500 mg (extended release) tablet. The Committee further noted that the formulation 'Sitagliptin' has become off-patent on 5th/6th July 2022.

1.2. The Committee recalled the decision taken in its 40th meeting dated 14.03.2022 and approved by the Authority in its 96th meeting dated 24.03.2022 regarding retail price fixation of FDCs of 'Sitagliptin and Metformin tablet' in which the Authority decided as follows:

(i) The Authority noted that the formulation "Sitagliptin" has become/ is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.

2

File No.12(7)/2021/DP/NPPA/Div.II(Vol.VI)

(ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:

"....The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

(iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved the fixation of the price of new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.

1.3 The Committee also noted the decision taken in its 41st, 42nd, 43rd, 44th and 45th meeting dated 08.04.2022, 02.06.2022, 04.07.2022, 04.08.2022 and 13.09.2022 is in line with the decision taken as mentioned Para 1.2 above and the same was approved by the Authority in its 97th meeting dated 06.05.2022, 99th meeting dated 28.06.2022, 100th meeting dated 05.08.2022, 101st meeting dated 07.09.2022 and 102nd meeting dated 27.09.2022 regarding retail price fixation of FDCs of 'Sitagliptin and Metformin tablet'.

1.4 Accordingly, the Committee recommended the retail price of FDCs of Sitagliptin + Metformin Hydrochloride IP tablet for various companies as detailed below:

1.4.1 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Ravenbhel Healthcare Private Limited (Manufacturer) and M/s Lupin Limited (Marketer) at Rs. 21.56 per tablet excluding GST as detailed below:

S. No.	Particulars	Source / Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release Form)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27



(b)	50% of (a)		18.63
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		22.29
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		21.56
(g)	Claimed Retail price		39.28
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 1000mg (ER) tablet" as per Pharmatrac Data for February, 2022		NA
(i)	Recommended retail price		21.56

1.4.2 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg (as Extended Release) for M/s Ravenbhel Healthcare Private Limited (Manufacturer) and M/s Unison Pharmaceuticals Private Limited (Marketer) at Rs. 18.67 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per February, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		19.05
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out Retail Price (d)-(e)		18.67
(g)	Claimed Retail price		18.67

File No.12(7)/2021/DP/NPPA/DIV.II(Vol.VI)

S. No.	Particulars	Source/Method	Amount (Rs.)
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 500mg (ER) tablet" as per Pharmatrac Data for February, 2022		NA
(i)	Recommended retail price		18.67

1.4.3 Each film coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg for M/s Mediforce Healthcare Private Limited (Manufacturer) and M/s Mankind Prime Labs Private Limited (Marketer) at Rs. 18.34 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 500 mg		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per February, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin IR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.51
(d)	Retail Price		18.64
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.30
(f)	Worked out Retail Price (d)-(e)		18.34
(g)	Claimed Retail price		22.00
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 500mg tablet" as per Pharmatrac Data for February, 2022		22.39
(i)	Recommended retail price		18.34

1.4.4 Each film coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg for M/s Mediforce Healthcare Private Limited (Manufacturer) and M/s Mankind Prime Labs Private Limited (Marketer) at Rs. 20.02 per tablet excluding GST as detailed below:

Q

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per February, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin IR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.61
(d)	Retail Price		20.74
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.72
(f)	Worked out Retail Price (d)-(e)		20.02
(g)	Claimed Retail price		25.00
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 1000mg tablet' as per Pharmatrac Data for February, 2022		22.97
(i)	Recommended retail price		20.02

1.4.5 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Ravenbhel Healthcare Private Limited (Manufacturer) and M/s Unison Pharmaceuticals Private Limited (Marketer) at Rs. 20.06 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 50 mg tablet	Retail price (as per February, 2022 data)	34.27
(b)	50% of (a)		17.13
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated	3.66

File No.12(7)/2021/DP/NPPA/DIV.II(Vol.VI)

S. No.	Particulars	Source/Method	Amount (Rs.)
		25.03.2021]	
(d)	Retail Price		20.79
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		20.06
(g)	Claimed Retail price		20.06
(h)	Retail price of FDC of 'Sitagliptin 50mg + Metformin 1000mg (ER) tablet" as per Pharmatrac Data for February, 2022		NA
(i)	Recommended retail price		20.06

1.4.6 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release) for M/s Ravenbhel Healthcare Private Limited (Manufacturer) and M/s Unison Pharmaceuticals Private Limited (Marketer) at Rs. 20.17 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(d)	Retail Price		20.55
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out Retail Price (d)-(e)		20.17
(g)	Claimed Retail price		20.17

Ar

S. No.	Particulars	Source/Method	Amount (Rs.)
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 500mg (ER) tablet" as per Pharmatrac Data for February, 2022		NA
(i)	Recommended retail price		20.17

1.4.7 Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Ravenbhel Healthcare Private Limited (Manufacturer) and M/s Unison Pharmaceuticals Private Limited (Marketer) at Rs. 21.56 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)		
(a)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27
(b)	50% of (a)		18.63
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(d)	Retail Price		22.29
(e)	Less 20% of the lower of (b) or (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out Retail Price (d)-(e)		21.56
(g)	Claimed Retail price		21.56
(h)	Retail price of FDC of 'Sitagliptin 100mg + Metformin 1000mg (ER) tablet" as per Pharmatrac Data for February, 2022		NA
(i)	Recommended retail price		21.56

2. Agenda No. 2 - Retail price fixation under Para 5 of DPCO, 2013 – Fixed Dose Combinations (FDCs) of Dapagliflozin + Sitagliptin + Metformin tablet.

File No.12(7)/2021/DP/NPPA/DIV.II(Vol.VI)

2.1. The Committee noted that three applications have been received for retail price fixation of two Fixed Dose Combinations (FDCs) of Dapagliflozin + Sitagliptin + Metformin tablets i.e. (i) Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin (ER) 1000 mg Tablet, (ii) Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin (ER) 500 mg tablet. The Committee further noted that the formulation 'Dapagliflozin and Sitagliptin' of the FDCs was patented and the patent expired on 02.10.2020 and 5th/6th July 2022 respectively.

2.2. In this connection, it is mentioned that the Authority in its 96th meeting dated 24.03.2022 (based on the recommendation of the Committee of Experts in its 40th meeting dated 14.03.2022) approved the retail price of the FDC of Sitagliptin + Metformin tablet in line with the following methodology as detailed below:

(i) The Authority noted that the formulation "Sitagliptin" has become/ is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.

(ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:

"...The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

(iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved the fixation of the new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.

2.3. The Committee also noted the decision taken in its 41st, 42nd, 43rd, 44th and 45th meeting dated 08.04.2022, 02.06.2022, 04.07.2022, 04.08.2022 and 13.09.2022 is in line with the decision taken as mentioned Para 1.2 above and the same was approved by the Authority in its 97th meeting dated 06.05.2022, 99th meeting dated 28.06.2022, 100th meeting dated 05.08.2022, 101st meeting dated 07.09.2022 and

102nd meeting dated 27.09.2022 regarding retail price fixation of FDCs of 'Sitagliptin and Metformin tablet'.

2.4. Accordingly, the retail price of FDCs of Dapagliflozin + Sitagliptin + Metformin tablets has been attempted in line with principles as adopted earlier i.e. reduction of 50% from the patented component i.e. Dapagliflozin and Sitagliptin and then adding the ceiling price of the scheduled components as applicable six month earlier from the date of application [termed as (d)]. From the total, a reduction of 20% of the lower of three component in line with the recommendation of the Pronab Sen Committee is provided.

2.5. Accordingly, the Committee deliberated upon the same and recommended the retail price of FDCs of Dapagliflozin + Sitagliptin + Metformin Hydrochloride IP tablet for various companies as detailed below:

2.5.1 Each film coated tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Sun Pharma Laboratories Limited (Manufacturer and Marketer) at Rs. 22.32 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)		
	Patent Component		
(a)	Derived retail price of Dapagliflozin 10 mg tablet	Retail price (as per February, 2022 data)	18.28
(b)	50% of Patent Component		9.14
(c)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27
(d)	50% of Patent Component		18.63
(e)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(f)	Less 20% of the lower of (b), (d) and (e) as recommended in the Pronab Sen Committee report		0.73
(g)	Worked out Retail Price (b)+(d)+(e)-(f)		30.70
(h)	Claimed Retail price		22.32

File No.12(7)/2021/DP/NPPA/Div.II(Vol.VI)

S. No.	Particulars	Source/Method	Amount (Rs.)
(i)	Retail price of FDC of 'Dapagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for February, 2022		NA
(j)	Recommended retail price		22.32

2.5.2. Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release) for M/sAlkem Laboratories Limited (Manufacturer and Marketer) at Rs. 29.31 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 500 mg (as Extended Release)		
(a)	Derived retail price of Dapagliflozin 10 mg tablet	Retail price (as per February, 2022 data)	18.28
(b)	50% of Patent Component		9.14
(c)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27
(d)	50% of Patent Component		18.63
(e)	Metformin CR 500 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	1.92
(f)	Less 20% of the lower of (d) or (e) as recommended in the Pronab Sen Committee report		0.38
(g)	Worked out Retail Price (b)+(d)+(e)-(f)		29.31
(h)	Claimed Retail price		44.64
(i)	Retail price of FDC of 'Dapagliflozin 10mg + Sitagliptin 100mg + Metformin 500mg (ER) tablet' as per Pharmatrac Data for February, 2022		NA

R

S. No.	Particulars	Source/Method	Amount (Rs.)
(j)	Recommended retail price		29.31

2.5.3. Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg, Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg and Metformin Hydrochloride IP 1000 mg (as Extended Release) for M/s Alkem Laboratories Limited (Manufacturer and Marketer) at Rs. 30.70 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg + Metformin Hydrochloride IP 1000 mg (as Extended Release)		
(a)	Derived retail price of Dapagliflozin 10 mg tablet	Retail price (as per February, 2022 data)	18.28
(b)	50% of Patent Component		9.14
(c)	Derived retail price of Sitagliptin 100 mg tablet	Retail price (as per February, 2022 data)	37.27
(d)	50% of Patent Component		18.63
(e)	Metformin CR 1000 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	3.66
(f)	Less 20% of the lower of (d) or (e) as recommended in the Pronab Sen Committee report		0.73
(g)	Worked out Retail Price (b)+(d)+(e)-(f)		30.70
(h)	Claimed Retail price		46.42
(i)	Retail price of FDC of 'Dapagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg (ER) tablet' as per Pharmatrac Data for February, 2022		NA
(j)	Recommended retail price		30.70

3. Agenda No. 3 - Retail price fixation under Para 5 of DPCO, 2013- Each Sachet Contains: Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium

R

Bicarbonate as buffer) for M/s Alkem Laboratories Ltd. (Manufacturer & Marketer).

3.1 The matter was deliberated in 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022 and the retail price of Rs. 7.30 per tablet excluding GST calculated for Pantoprazole 40 mg tablet was extended to Sachet Containing Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium Bicarbonate as buffer). This was done because the Committee was of the opinion that there is no variation in the route of administration between tablet and sachet and both the dosage form can be considered as similar for therapeutic point of view.

3.2 M/s Alkem Laboratories Limited represented vide letter dated 26.09.2022 and stated that their formulation is different from conventional tablet in view of low-RH area, micronized API, special equipment used for drying process of excipients, filling sealing and nitrogen purging in sachets, special packing materials benefits of pan insta technology etc.

3.3 The matter was also placed before the Authority in its 102nd meeting held on 27.09.2022 in which the Authority noted the representation of M/s Alkem Laboratories Ltd and decided that the matter be referred back to the Committee of Experts for examination of the representation.

3.4 Further, M/s Alkem Laboratories Ltd also submitted letter dated 07.10.2022 vide its e-mail dated 08.10.2022 requesting for consideration of equivalence of pantoprazole sachet with Omeprazole Sachet and equivalence of Omeprazole Tab/Capsules with Pantoprazole Tab/Capsules for calculation of retail price.

3.5 M/s Alkem Laboratories Ltd gave a presentation before the committee through VC on their claim made vide representation dated 26.09.2022 & 08.10.2022 of their formulation.

3.6. Committee noted the presentation and agreed that the formulation Pantoprazole powder for oral suspension may be useful in patients who have difficulty in swallowing tablets like patients with dysphagia, oesophageal strictures, recent radiation or chemotherapy.

3.7. The Committee further noted that the formulation "Pantoprazole" and "Omeprazole" are of same therapeutic category and accordingly the retail price of Pantoprazole Sachet can be calculated based on the equivalent pricing structure/ drug contents/ dosage type and strength as that of Omeprazole. Therefore, the committee recommended the retail price of each Sachet Containing Pantoprazole Sodium Eq. to Pantoprazole 40mg (Sodium Bicarbonate as buffer) for M/s Alkem Laboratories Ltd. (Manufacturer & Marketer) as below:

a. *Applicable Ceiling price of Omeprazole 20mg tablet as on November 2021 = Rs. 4.94 per tablet excluding GST [SO. 1330(E) dated 25.03.2021]*

b. *Applicable Ceiling price of Omeprazole Powder for oral suspension 20mg as on November 2021 = Rs. 6.15 per sachet containing 5gm of finished formulation excluding GST (Rs. 1.23 per gram excluding GST [SO. 1330(E) dated 25.03.2021])*

c. *Derived ratio of Omeprazole 20mg Tablet & 20mg powder for oral suspension (5gm)*

= Rs. 6.15 / Rs. 4.94 = 1.24

d. Retail price of Pantoprazole 40mg tablet as per Pharmatrac database for the month of November 2021 = Rs. 7.30 per tablet

e. Derived Retail Price of Pantoprazole 40mg Powder for Oral suspension (5gm of finished formulation) by applying ratio (as per point C) on the price as per point (d) above

= Rs. 7.30 per tablet X 1.24 = Rs. 9.05 per sachet of 5gm finished formulation containing 40mg Pantoprazole excluding GST

f. Retail Price claimed by the company = Rs. 44 per sachet of 5gm excluding GST

g. Recommended Price of Pantoprazole 40mg for M/s Alkem Laboratories Ltd. (Manufacturer & Marketer): Lower of (e) & (f) above:

= Rs. 9.05 per sachet of 5gm finished formulation containing 40mg Pantoprazole excluding GST

4. Agenda No. 4 - Retail price fixation under Para 5 of DPCO, 2013- Each Adhesive Patch contains "Lidocaine 700mg in an aqueous base (50mg per gm adhesive) for M/s Hetero Healthcare Limited (Manufacturer and Marketer).

4.1 The matter was deliberated in 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022 and retail price of Lidocaine 700mg patch was calculated by applying the ratio of Fentanyl Injection to Patches on Lidocaine Injection to patches. Committee recommended the retail price of each Adhesive Patch containing "Lidocaine 700mg in an aqueous base (50mg per gm adhesive) for M/s Hetero Healthcare Limited (Manufacturer and Marketer) at Rs 9.94 per patch excluding GST (being lower than the price claimed by the company at Rs. 44.64 per patch excluding GST).

4.2 M/s Hetero Healthcare Ltd made representation on the price recommended by the Committee vide letter dated 20.09.2022 and stated that patches cannot be considered at par with injection as both have different drug delivery system. The company further submitted the list of prices of fentanyl patches with MRP and the list of Lidocaine patches available in the market.

4.3 The matter was also placed before the Authority in its 102nd meeting held on 27.09.2022 in which the Authority noted the representation of M/s Hetero Healthcare Ltd and decided that the matter be referred to the Committee for examination of the representation.

4.4 M/s Hetero Healthcare Ltd made presentation in person before the Committee and also furnished the sample of Lidocaine Patch 350mg of another manufacturer available in the market. Company also stated that Lidocaine Patches are available in the market as claimed for other manufacturers also, but the same are not reflected in AWACS database due to low demand of the patches.

4.5 Committee noted the submission of the company and after deliberation decided that the claim of the company may be verified and retail prices may be calculated based on the market data of others manufacture/marketer companies.

5. Agenda No. 5: Application by M/s Sachin Parenterals Ltd for Price approval of (i) Dextrose Injection IP (5% w/v) 250ml and (ii) Glucose 5% with sodium chloride 0.9% w/v 250ml having special features- Euro Head bottle.

5.1 The matter was deliberated in 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022 and recommended separate ceiling prices. The recommendation of MDC was placed in 102nd meeting of the Authority held on 27.09.2022 in which the Authority noted that the separate price as recommended for these IV fluids are not in line with the special ceiling price provided to other strength/ pack size of IV fluids and decided that the matter be referred to the Committee for re-examination.

5.2 Committee noted the decision of the Authority and after deliberation decided that the detailed examination based on Authority's observation be placed in next meeting of the Multidisciplinary Committee of Experts.

6. Agenda No. 6: Application for "Special Feature rate" for scheduled products (i) Tazofic Injection 2.25 gm containing Piperacillin 2gm+Tazobactam 250mg and (ii) Tazofic Injection 4.5 gm containing Piperacillin 4gm+Tazobactam 500 mg under Para 11(3) of DPCO 2013.

6.1 The matter was deliberated in 45th meeting of the Multidisciplinary Committee of Experts held on 13.09.2022, wherein the committee recommended additional 15 percent price over the present applicable ceiling price of the formulation for incremental innovation of the packaging.

6.2 M/s Gufic Biosciences Ltd made representation on the recommendation made by the Multidisciplinary Committee of Experts vide letter dated 23.09.2022. The matter was also placed before the Authority in its 102nd meeting held on 27.09.2022 in which the Authority decided that the representation of the company be referred to the Committee for examination.

6.3 Committee noted the representation of the company and after deliberation decided that the company may be asked to submit the additional literature to substantiate their claim and also to make presentation in the next meeting of the committee.

7. Agenda No. 7: Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Zydus Healthcare Limited (marketer).

7.1 The committee observed that the therapeutic category/use of formulation claimed by the applicant "For short term treatment of moderate pain" is not correct. Further, it is also observed that Cardiovascular medicines is stated in size of packs. Therefore, Committee noted that the therapeutic category of the formulation is Lipid Lowering Agent.

7.2 The committee recommended the retail price of Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Zydus Healthcare Limited (marketer) as below:



S. No	Particulars	Source/Method	Amount (Rs.)
	Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg		
(a)	Derived retail price of Atorvastatin 80 mg tablet	Retail price (as per the formula of Pranob Sen Committee) – Note 1	34.81
(b)	Derived retail price of Bempedoic Acid 180 mg tablet	Retail Price [as per Pharmatrac data for the period from June, 2021 to May, 2022 as no data is available in Pharmatrac database for the months prior to 6 months before the date of application and Pharmatrac database used is for the month of September, 2022]	19.88
(c)	Total (a) + (b)		54.69
(d)	Less 20% of the lower of (a) or (b) as recommended in the Pronab Sen Committee report		3.98
(e)	Worked out Retail Price (c)-(d)		50.71
(f)	Claimed Retail price		98.00
(g)	Recommended retail price		50.71

Note 1:

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectibles.

File No.12(7)/2021/DP/NPPA/DIV.II(Vol.VI)

- a) Ceiling price of Atorvastatin 40 mg tablet as on March, 2022 = Rs. 19.34 per tablet excluding GST [S.O. No. 1330(E) dated 25.03.2021]
- b) Derived price of Atorvastatin 80mg tablet after applying the formula of Pronab Sen Committee on the price as per (a) above
- = $19.34[1+0.80\{80-40/40\}] = \text{Rs.}34.81$ per tablet excluding GST

8. Agenda No. 8: Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Sun Pharma Laboratories Limited (marketer).

8.1 The committee recommended the retail price of Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg for M/s Exemed Pharmaceuticals (manufacturer) and M/s Sun Pharma Laboratories Limited (marketer) as below:

S. No	Particulars	Source / Method	Amount (Rs.)
	Each film coated tablet containing Atorvastatin Calcium IP eq. to Atorvastatin 80mg and Bempedoic Acid 180mg		
(a)	Derived retail price of Atorvastatin 80 mg tablet	Retail price (as per the formula of Pranob Sen Committee) – Note 1	34.81
(b)	Derived retail price of Bempedoic Acid 180 mg tablet	Retail Price [as per Pharmatrac data for the period from June, 2021 to May, 2022 as no data is available in Pharmatrac database for the months prior to 6 months before the date of application and Pharmatrac database used is for the month of September, 2022]	19.88
(c)	Total (a) + (b)		54.69
(d)	Less 20% of the lower of (a) or (b) as recommended in the Pronab Sen Committee report		3.98
(e)	Worked out Retail Price (c)-(d)		50.71
(f)	Claimed Retail price		53.57
(g)	Recommended retail price		50.71

Note 1:

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$$

Where: P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a = 0.8 for tablet / capsule and 0.7 for injectibles.

a) Ceiling price of Atorvastatin 40 mg tablet as on March, 2022 = Rs. 19.34 per tablet excluding GST [S.O. No. 1330(E) dated 25.03.2021]

b) Derived price of Atorvastatin 80mg tablet after applying the formula of Pronab Sen Committee on the price as per (a) above

$$= 19.34[1+0.80\{80-40/40\}] = \text{Rs.}34.81 \text{ per tablet excluding GST}$$

9. Agenda No. 9: Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Telmisartan IP 40mg and Bisoprolol Fumarate IP 5mg for M/s Micro Labs Limited (manufacturer and marketer).

9.1 The committee recommended the retail price of Each film coated tablet containing Telmisartan IP 40mg and Bisoprolol Fumarate IP 5mg for M/s Micro Labs Limited (manufacturer and marketer) as below:

S. No	Particulars	Source / Method	Amount (Rs.)
	Each film coated tablet containing Telmisartan IP 40mg and Bisoprolol Fumarate IP 5mg		
(a)	Telmisartan IR 40 mg	Ceiling Price [SO. 1330(E) dated 25.03.2021]	6.61
(b)	Derived retail price of Bisoprolol Fumarate IP 5mg tablet	Retail price (as per March, 2022 data)	6.50
(c)	Total (a) + (b)		13.11
(d)	Less 20% of the lower of (a) or (b) as recommended in the Pronab Sen Committee report		1.30
(e)	Worked out Retail Price (c)-(d)		11.81
(g)	Claimed Retail price		19.64
(i)	Recommended retail price		11.81

10. Agenda No. 10: Application by M/s Intas Pharmaceuticals Ltd for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulations "Clozapine Extended Release Capsules 12.5 mg/ 25 mg/ 50 mg/ 100 mg/ 200 mg".

10.1 The committee noted that the matter was deliberated in 44th meeting of the Multidisciplinary Committee of Experts held on 04.08.2022, wherein it recommended as follows:

11.1 The Committee noted the application filed by M/s Intas Pharmaceuticals Ltd for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulations "Clozapine Extended Release Capsules 12.5 mg/ 25 mg/ 50 mg/ 100 mg/ 200 mg".

11.2 The Committee deliberated upon the matter in detail and is of the opinion that the different variants of a drug like extended release, sustained release, modified release of a drug are in the market since a considerable period and also manufactured by a number of companies. Hence, it cannot be considered as 'a new delivery system' for qualifying for exemption under Para 32(iii) of DPCO 2013. Accordingly, the Committee decided to reject the application of M/s Intas Pharmaceuticals Ltd for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (iii) for the formulations "Clozapine Extended Release Capsules 12.5 mg/ 25 mg/ 50 mg/ 100 mg/ 200 mg."

10.2 Committee also noted the representation of M/s Zydus Healthcare Ltd received vide e-mail dated 23.08.2022 and representation of M/s Intas Pharmaceuticals Ltd dated 07.09.2022.

10.3 Committee deliberated on the matter in view of representations received and reiterated its decision taken in 44th meeting of the Multidisciplinary Committee of Experts held on 04.08.2022 as mentioned above.

The meeting ended with a vote of thanks to all.

Rashmi
20/10/2022
(Rashmi Tahiliani)
Jt. Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on February, 2022 Data under Para 5 of DPCO, 2013

Each film coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 50 mg + Metformin Hydrochloride IP 1000 mg

Number of Companies consisting of Market Share of 1% & Above					2
Sum of MAT value considered for price calculation (in Lakhs)					21,328.23
Sum of PTR per unit considered for price calculation					39.59
Number of Packs considered					2
Average PTR					19.80
Add : 16% Retailer Margin					3.17
Retail Price (without local taxes)					22.97
% Reduction with compared to Highest Price					0.15%

Minimum Price (Rs.)			19.76
Maximum Price (Rs.)			19.83
Average of all considered (Rs.)			19.80
Retail Price (Rs.)			22.97

S.No.	पैकेजिंग Pack Description	ब्रांड BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR	21328,22,823	100%	M3			Price per unit (Rs.)	Price per unit (Rs.) Considered
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No			
1	ISTAMET 50/1000 MG TABLET 15	ISTAMET	SUN PHARMA LABORATORIES LTD.	50/1000 MG	15	TABLET	297.44	575890473	27.00%	27.00%	Y	19.83	19.83	
2	JANUMET 50/1000 MG TABLET 15	JANUMET	MSD PHARMACEUTICALS PRIVATE LTD.	50/1000 MG	15	TABLET	296.43	1556932350	73.00%	73.00%	Y	19.76	19.76	
		Rs. Per Tablet												
	Worked out Retail Price	22.97	Excluding GST											

4

Computation of Retail Price based on February, 2022 Data under Para 5 of DPCO, 2013

Each film coated bilayered tablet containing Sitagliptin 50 mg	Number of Companies consisting of Market Share of 1% & Above					2
	Sum of MAT value considered for price calculation (in Lakhs)					7,728.31
	Sum of PTR per unit considered for price calculation					59.08
	Number of Packs considered					2
	Average PTR					29.54
	Add : 16% Retailer Margin					4.73
	Retail Price (without local taxes)					34.27
% Reduction with compared to Highest Price						0.17%

Minimum Price (Rs.)			29.49
Maximum Price (Rs.)			29.59
Average of all considered (Rs.)			29.54
Retail Price (Rs.)			34.27

S.No.	Pack Description	BRAND	Company	Strength	Pack Size	Unit	PTR	7728,31,152	100%	Brandwise MAT (Ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
								MAT(Rs.)	SKU wise MAT %				
1	ISTAVEL 50 MG TABLET 7	ISTAVEL	SUN PHARMA LABORATORIES LTD.	50 MG	7	TABLET	206.43	214132523	27.71%	27.71%	Y	29.49	29.49
2	JANUVIA 50 MG TABLET 7	JANUVIA	MSD PHARMACEUTICALS PRIVATE LTD.	50 MG	7	TABLET	207.14	558698629	72.29%	72.29%	Y	29.59	29.59
		Rs. Per Tablet											
	Worked out Retail Price	34.27	Excluding GST										

Computation of Retail Price based on February, 2022 Data under Para 5 of DPCO, 2013

Each film coated tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg	Number of Companies consisting of Market Share of 1% & Above	14
	Sum of MAT value considered for price calculation (in Lakhs)	41,532.12
	Sum of PTR per unit considered for price calculation	252.17
	Number of Packs considered	16
	Average PTR	15.76
	Add: 16% Retailer Margin	2.52
Retail Price (without local taxes)	18.28	
% Reduction with compared to Highest Price	61.52%	

Minimum Price (Rs.)	7.74
Maximum Price (Rs.)	40.96
Average of all considered (Rs.)	15.76
Retail Price (Rs.)	18.28

S.No.	Pack Description	BRAND	Company	Strength	Pack Size	Unit	PTR	45664,83,474	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Quality (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
1	4 DAPA 10 MG TABLET 10	4 DAPA	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	85.00	516545	0.01%	0.01%	N	8.50	
2	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	380160	0.01%	0.01%	N	10.29	
3	DAGUPACK 10 MG TABLET 10	DAGUPACK	KOYE PHARMACEUTICALS PVT. LTD.	10 MG	10	TABLET	99.29	3641659	0.08%	0.08%	N	9.93	
4	DAJO 10 MG TABLET 15	DAJO	MICRO LABS LTD	10 MG	15	TABLET	126.43	34826534	0.76%	0.76%	N	8.43	
5	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	101.43	84620716	1.85%	1.85%	Y	10.14	10.14
6	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	HBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	150.00	11787298	0.26%	0.26%	N	10.00	
7	DAPABEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD	10 MG	10	TABLET	100.00	10531800	0.23%	0.23%	N	10.00	
8	DAPABITE 10 MG TABLET 10	DAPABITE	CORONA	10 MG	10	TABLET	106.43	94335933	2.07%	2.07%	Y	10.64	10.64
9	DAPABUS 10 MG TABLET 10	DAPABUS	MED MANOR ORGANICS PVT LTD.	10 MG	10	TABLET	82.14	203214	0.00%	0.00%	N	8.21	
10	DAPACARE 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	78.57	446906	0.01%	0.01%	N	7.86	
11	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENOV	10 MG	15	TABLET	181.07	1991408	0.04%	0.04%	N	12.07	
12	DAPACOSE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	85.72	26433476	0.58%	0.58%	N	8.57	
13	DAPADEL 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	106.43	3782522	0.08%	0.08%	N	10.64	
14	DAPAEASE 10 MG TABLET 10	DAPAEASE	JUBILANT GENERICS LIMITED	10 MG	10	TABLET	103.57	779364	0.02%	0.02%	N	10.36	
15	DAPAGAIN 10 MG TABLET 15	DAPAGAIN	SYSTEMIC LABORATORIES LTD-MEM	10 MG	15	TABLET	63.22	4215510	0.09%	0.09%	N	4.21	
16	DAPAGLYN 10 MG TABLET 15	DAPAGLYN	ZYDIUS CADILA - ZHL	10 MG	15	TABLET	200.36	244538767	5.36%	5.36%	Y	13.36	13.36
17	DAPAGREAT 10 MG TABLET 15	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	142.14	6791876	0.15%	0.15%	N	9.48	
18	DAPAHENZ 10 MG TABLET 15	DAPAHENZ	LA RENOV	10 MG	15	TABLET	181.07	4857203	0.11%	0.11%	N	12.07	
19	DAPAKAY 10 MG TABLET 10	DAPAKAY	PRECIA PHARMA	10 MG	10	TABLET	103.57	6854263	0.15%	0.15%	N	10.36	
20	DAPALEX 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	110.71	33970448	0.74%	0.74%	N	11.07	
21	DAPAMAC 10 MG TABLET 10	DAPAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	101.43	133375277	2.92%	2.92%	Y	10.14	10.14
22	DAPANORM 10 MG TABLET 10	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125.00	175967875	3.85%	3.85%	Y	12.50	12.50
23	DAPANOVA 10 MG TABLET 15	DAPANOVA	MEDLEY PHARMACEUTICALS	10 MG	15	TABLET	128.57	39512261	0.87%	0.87%	N	8.57	
24	DAPAONE 10 MG TABLET 10	DAPAONE	MSN LABORATORIES LTD	10 MG	10	TABLET	107.14	24719662	0.54%	0.54%	N	10.71	
25	DAPARAY 10 MG TABLET 10	DAPARAY	ICON LIFESCIENCES	10 MG	10	TABLET	69.64	738671	0.02%	0.02%	N	6.96	
26	DAPARYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	92.86	169923043	3.72%	3.72%	Y	9.29	9.29
27	DAPASIS 10 MG TABLET 10	DAPASIS	AKESHIS PHARMA (P) LTD	10 MG	10	TABLET	99.29	5990464	0.13%	0.13%	N	9.93	
28	DAPASPEC 10 MG TABLET 10	DAPASPEC	SPECTRA THERAPEUTICS PVT. LTD.	10 MG	10	TABLET	96.43	1376419	0.03%	0.03%	N	9.64	
29	DAPATEN 10 MG TABLET 15	DAPATEN	BAL PHARMA	10 MG	15	TABLET	117.54	78399	0.00%	0.00%	N	7.84	
30	DAPATREND 10 MG TABLET 14	DAPATREND	ANTHEM BIOPHARMA PVT LTD	10 MG	14	TABLET	165.00	5398965	0.12%	0.12%	N	11.79	
31	DAPATURN 10 MG TABLET 10	DAPATURN	LUPIN LTD	10 MG	10	TABLET	103.57	16091878	0.35%	0.35%	N	10.36	
32	DAPAVEL 10 MG TABLET 10	DAPAVEL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	92.86	214524938	4.70%	4.70%	Y	9.29	9.29
33	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	103.57	54685	0.00%	0.00%	N	10.36	

25

